FBP vaccine: Completed Phase IIa enrollment

Galena completed enrollment of 45 HLA-A2-positive or HLA-A2-negative patients with ovarian or endometrial cancer in an open-label, U.S. Phase IIa trial evaluating 1,000 Ug intradermal GALE-301 plus GM...